In-depth interpretation: The anti-cancer mechanism and clinical value of trastuzumab

The name Fam-trastuzumab deruxtecan-nxki (Fam-trastuzumab deruxtecan-nxki) is gradually becoming well-known in the anti-cancer field. As a cutting-edge anti-cancer drug, it specifically targets HER2-positive breast cancer, non-small cell lung cancer, and gastric cancer, showing significant therapeutic potential. Trastuzumab is unique in that it is a perfect combination of an elongated DNA topoisomerase I (Topo I) inhibitor and a HER2 antibody-targeted therapy.

This drug has a trio of anti-cancer mechanisms. Trastuzumab can precisely bind to the HER2 receptor on the surface of cancer cells, thereby blocking the HER2 signaling pathway. This step seems to cut off the "lifeline" of cancer cells, effectively inhibiting the proliferation and survival ability of cancer cells. The drug cleverly uses HER2 receptor-mediated endocytosis to precisely deliver cytotoxic drugs into cancer cells. These cytotoxic drugs are released inside cancer cells, triggering their death.

In clinical trials, the efficacy of trastuzumab has been impressive. It serves as a ray of light for patients whose condition continues to worsen despite multiple treatment options. The drug not only shows excellent anti-tumor activity, but also achieves remarkable results in prolonging patients' survival and alleviating symptoms, bringing real hope to patients.

Trastuzumab also comes with certain risks. Possible side effects include common symptoms such as nausea, vomiting, and diarrhea, as well as more serious reactions such as fatigue and leukopenia. More importantly, for some specific patients, it may also cause serious adverse reactions such as cardiotoxicity and interstitial lung disease. Therefore, before using this drug, doctors need to conduct a thorough physical evaluation of the patient and closely monitor their response to the drug.